Press ReleasesHempStreet Announces Partnership With MGC Pharma To Revolutionise Global...

HempStreet Announces Partnership With MGC Pharma To Revolutionise Global Phytomedicine Sector


MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company‘), a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce a partnership with HempStreet, India’s first research to retail venture in the medicinal cannabis sector.

Headquartered in the UK, MGC Pharma has been working on polyherbal formulations based on cannabis and other phytopharmaceuticals. MGC Pharma has two proprietary formulations CimetrA™ and CannEpil©. CimetrA™ is effective in arresting the cytokine storm, a symptom of  COVID-19. It is made of natural-sourced ingredients including Artemisinin, Curcumin, and Boswellia serrata. CannEpil© is a phytocannabinoid-based medicine that effectively treats drug-resistant Epilepsy. Both products have undergone successful Phase II clinical trials.  Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA™, which had an immediate need as there are currently over 15 million individuals (approximately 30% of all Covid-19 recoverees in India) said to be experiencing some form of post- or long- Covid- 19 related symptoms.

The partnership will also accelerate HempStreet’s upcoming venture – transdermal delivery technology for cannabinoids – to launch in the markets beyond Asia with the help of MGC Pharma’s widespread distribution network in Australia, the UK, Brazil, and Ireland.

Commenting on the partnership,Abhishek Mohan, Co-founder of HempStreet, said: “We are very excited to work with Roby and the team at MGC Pharma, bringing cutting-edge, scientifically-validated phytopharmaceutical medicines to tackle mass ailments in India and beyond. In particular, CimetrA™, which has shown a 100% success rate in Phase II clinical trials in India, will be an important product just on account of the fact that an estimated 15 million individuals are experiencing some sort of Post Covid-19 / Long Covid symptoms.

Further, Roby Zomer, Co-founder, MGC Pharma, said: “Entry into significant global markets such as India is paramount to MGC Pharma’s agenda, advancing phytomedicine adoption globally. India has a long-established and government-supported Ayurvedic healthcare system, and working with HempStreet to facilitate access to our proprietary phytomedicines such as CimetrA and CannEpil© and the new formulations on the pipeline, is crucial to gaining a foothold in this market.”

MGC Pharma is leaving its mark in the global medical cannabis industry by developing and supplying top-quality phytocannabinoid medicines in Europe, North America, and Australasia. This partnership is a significant step for MGC Pharma to tap into the Asian market while helping HempStreet expand its global footprint.

Together with MGC Pharma, HempStreet is committed to bring well-researched, highly efficient, and responsibly-dispensed phytomedicines to tackle mass ailments faced by people worldwide. With this partnership, HempStreet aims to combine the R&D and distribution strengths of both companies to improve the quality of life for hundreds of millions of people.

Latest news

Poko Innovations, Inc. Receives Validation And Authorization To Sell 44 Items In The UK

POKO Innovations an award-winning UK-based collection of CBD-focused companies that bring innovative, inspiring solutions to the CBD industry through...

Intercure Posts More Record Results But Says It ‘Could Do So Much More’ If It Had More Supply

INTERCURE has released another set of ‘all time record quarterly’ results, seeing both revenues and profits skyrocket year-on-year.  Despite its...

Stenocare Delivers First Product Batch To The Danish Market

STENOCARE delivers the first product batch of their THC Oil to the Danish market. This means that the product is...

Chill Brands Targets Near £4m Capital Raise To Fund Fresh Strategy & £1.3m Domain

CHILL Brands’ shareholders have voted in favour of plans for a new £3.5m fundraise alongside a separate £484,000 open...

Cellular Goods Makes More Major Changes To Board In First Update Since Ingestibles Were Pulled (UPDATED)

Cellular Goods has released its first significant update since announcing that its ingestibles products were not legally allowed to...

European Cannabis Stocks Review: Akanda Dives Over 80% & Celadon Suffers After Reporting Huge Rise In Losses

This week was another difficult week for London Stock Exchange (LSE) listed cannabis companies, with every one of BusinessCann's...

Must read

Intercure Posts More Record Results But Says It ‘Could Do So Much More’ If It Had More Supply

INTERCURE has released another set of ‘all time record...

Chill Brands Targets Near £4m Capital Raise To Fund Fresh Strategy & £1.3m Domain

CHILL Brands’ shareholders have voted in favour of plans...

You might also likeRELATED
Recommended to you